Clinical TrialMay 28, 2026, 08:51 AM
Entera Bio EB613 Osteoporosis Data Accepted for Late Breaking Oral Presentation
AI Summary
Entera Bio Ltd. announced that new clinical data supporting its single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation at ENDO 2026. Additionally, abstracts for pre-clinical results of EB612 for hypoparathyroidism and PK-PD study results for EB618 for obesity and metabolic disorders were also accepted for presentation at the annual meeting. The company is a clinical-stage firm focused on oral peptide and protein replacement therapies.
Key Highlights
- New clinical data for Entera Bio's EB613 (oral PTH(1-34)) for osteoporosis selected for Late Breaking Oral Presentation.
- EB613 is the final candidate for a planned Phase 3 study in postmenopausal women with osteoporosis.
- Presentation scheduled for Sunday, June 14, 2026, at ENDO 2026 in Chicago.
- Pre-clinical results for EB612 (oral long-acting PTH(1-34) analog for hypoparathyroidism) accepted for presentation.
- PK-PD study results for EB618 (oral dual GLP-1/Glucagon Receptor Agonist for obesity) in non-human primates accepted.
- ENDO 2026 annual meeting takes place June 13-16, 2026.
Price Impact
More from ENTX